

Issue Date: 23 August 2023

GT Diagnostics announces release of HiPAL Pro, a self-administered assessment aiding diagnosis of dementia

- HiPAL Pro, a self-administered engaging and interactive tool, supporting clinicians in diagnosing cognitive impairments has been released in the USA
- HiPAL Pro is officially listed with the US Food and Drug Administration (FDA) as a computerised cognitive assessment aid

Genting TauRx Diagnostic Centre Sdn Bhd (GTD), a Malaysian based company, and its UK subsidiary, GT Diagnostics (UK) Ltd, jointly GT Diagnostics, today announced the release of HiPAL Pro, which is now available in the USA.

HiPAL Pro is a self-administered engaging and interactive tool that runs on a tablet. It supports clinicians by providing readily interpretable scores that professionally evaluate objective and subjective memory as well as mental processing speed. Through language agnostic testing, HiPAL Pro is designed to assist in the diagnosis and monitoring of dementia, in particular, Alzheimer's disease.

Director of GTD, Dato' Sri Tan Kong Han states "GT Diagnostics was formed to enable basic research in dementia diagnosis to transition into clinical development. With the release of our first clinical expert tool, HiPAL Pro, we see the first tangible fruit of this vision. Our dedicated team is working tenaciously towards release of more products that will transform the patient pathway in dementia in the near future."

Prof Bjoern Schelter, CEO of GT Diagnostics (UK) Ltd confirms "This is a huge milestone for GT Diagnostics. It is impressive to see what the team has achieved over the past years."

Dr Linda Sommerlade, Head of Operations of GT Diagnostics (UK) Ltd adds "HiPAL Pro is a tool that can be used in waiting rooms of primary care facilities or expert centres. This presents a first step in revolutionising the diagnosis of dementia. With novel treatments becoming available, the development of cutting-edge diagnostic solutions is key to make these treatments available to the right people early in the disease."

For additional information, please visit: <https://www.gtdiag.com/products/hipal-pro> or <https://hipalpro-app.com/>.



About HiPAL Pro

HiPAL Pro is a self-administered engaging and interactive tool that runs on a tablet. It supports clinicians by providing readily interpretable scores that professionally evaluate objective and subjective memory and mental processing speed. HiPAL Pro can be used in waiting rooms of primary care facilities or expert centres.

Through language agnostic testing, HiPAL Pro is designed to provide an advanced output aimed at assisting in the diagnosis and monitoring of dementia, in particular, Alzheimer's disease. With minimal set-up by the clinician, the application presents a self-administered psychometric test to the patient, examining aspects of cognition such as memory and executive function. Individual patient results are presented as predicted scores for well-established standard questionnaire-based assessments, allowing the clinician to evaluate their patient according to well-defined and characterised measures.

ABOUT GT Diagnostics

Genting TauRx Diagnostic Centre Sdn Bhd, a company established in Malaysia, and its wholly owned subsidiary GT Diagnostics (UK) Limited (collectively, "GT Diagnostics") was founded as a collaboration between Genting Berhad, a Malaysian company, and TauRx Pharmaceuticals Ltd group, with the vision to change the diagnostic landscape and market in dementia.

Our mission is to develop and provide much needed tools required for the early diagnosis and monitoring of disease progression in dementia; from tools that can be used in the comfort of one's home to tools that require administration by experts.

GT Diagnostics develops readily deployable e-platform tools for home use as well-being apps, alongside professional tools for expert use targeting the diagnosis and monitoring of dementias. Our tools are designed to be made available through various channels and service providers, ranging from financial and professional service providers, clinicians, residential and non-residential care centres, to specialised dementia centres.

GT Diagnostics (UK) Limited is based in Aberdeen.

CONTACT

Linda Sommerlade

contact@gtdiag.com